TheraRadar
← Back
Data updated: Jun 28, 2026

GATE PHARMS

Generics

GATE PHARMS is a generic drug manufacturer focused on Infectious Disease, Dermatology.

2016
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

GATE PHARMS's Key Drugs

GATE PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

GATE PHARMS's Recent FDA Approvals

New NDA/BLA approvals for GATE PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

GATE PHARMS's Therapeutic Areas

GATE PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
1 drugs
Dermatology 50%
1 drugs

GATE PHARMS's Top Competitors

GATE PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GATE PHARMS Pipeline Snapshot

Active clinical trials for GATE PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling